BioPact appoints new Vice President of Business Development

Fast Growing Company Secures Top Talent for Product Launch Initiative

Cambridge, MA – BioPact (company.bio-pact.com) announced that Lainie Mulvanny has joined the company to lead and support the organization’s much-anticipated launch of their research and development kits.  Mulvanny brings a wealth of industry experience from positions held at Sanofi-Genzyme, Merck, Zila Pharmaceuticals and CIBA vision.

Mulvanny joins BioPact as their VP of Business Development to build and oversee the new division.  Much excitement surrounds the R&D kit launch that has industry experts talking about MGMR® – the first of its kind truly medical grade carbon nanotube-derived material Bio-Pact is quickly becoming known for.   Mulvanny says “Joining BioPact is a tremendous opportunity for me to bring this revolutionary and powerful product to market.  The limitless applications of MGMR are about to change the pharmaceutical and medical landscape forever; it is truly very exciting to be part of it.”

Kent Phelps, CEO, says “On one hand it was quite a coup for a company as young as BioPact is to land someone of Lainie’s caliber to head up our MGMR R&D kit division. It is just one more validation, however, of the power of our revolutionary technology. With Lainie Mulvanny at the helm, we are confident development of MGMR in fields like targeted drug delivery will quickly proliferate as we get our material in the hands of as many medical researchers as possible through our new R&D kit offering.”

About BioPact

Some things are worth the wait. Though the pace of new technology increases every year, many in the medical field have been wondering how long the wait would be for one of today’s most promising breakthroughs: carbon nanotubes. Carbon nanotubes – or CNTs – have been around for years. Impressive lab results achieved with CNTs in fields like targeted drug delivery have been generating excitement among medical researchers for decades. BioPact has made carbon nanotubes worth the wait, transforming CNTs into a new composition of matter: Medical Grade Molecular Rebar – or MGMR. Unlike the dirty micron bundles medical researchers have come to expect, MGMR overcomes the toxicity, dispersibility and scalability challenges of the other CNTs on the market. MGMR will not only lead to revolutionary innovation in devices, diagnostics, and regenerative medicine, it’ll breathe new life into hundreds of existing drugs with toxicity issues or expiring patents.

Contact

Kent Phelps, CEO
245 First Street 18th Floor
Cambridge MA 02142-1292
E: inquires@bio-pact.com
Tel. 800.561.7087